AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05896202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TMS Video
Description: One third of the participants will see the TMS video once in person. The video will be 2-3 minutes in length and contain information on the procedures of the technique and what participants should expect to feel/experience.
Study NCT06615219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intergroup contact training
Description: The intervention program uses direct contact and four types of indirect contact as the intervention strategy and general framework, and is divided into three main steps, assessing and reflecting on aging stereotypes, carrying out indirect and direct contact, and evaluating the effectiveness of the intervention. The time period is 12 weeks, with the interventionists comprising the researcher and nursing students. The forms of the intervention include holding mini-lectures, organizing participation in voluntary activities, and nostalgia interviews.
Study NCT06615219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular course training only
Description: The specific process is to sign in the classroom, review the knowledge of the previous class by asking questions, introduce the content of the new class, the teacher explains the knowledge points according to the teaching objectives and teaching content, and finally assigns the post-class homework of the course content. At the end of the experiment, the control group was given compensatory intervention.
Study NCT06675747 — intervention group
Intervention type: OTHER
Intervention: Ultrasound imaging
Description: To investigate the mechanism of action of occlusal splints, a routinely applied treatment method for myogenic temporomandibular disorders, ultrasound images will be taken from all patients before and after treatment, and measurements will be conducted based on these images.
Study NCT06626126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ApoB-guided-LLT
Description: Patients in this group will receive treatment regimens adjusted accordingly to meet the Apolipoprotein B targets
Study NCT06626126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LDL-C-guided-LLT
Description: Patients in this group will receive treatment regimens adjusted accordingly to meet the LDL-C targets.
Study NCT06588101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written informed consent with infographic
Description: Potential participants are provided a visual infographic depicting the key elements of the written consent form in addition to the standard written consent form.
Study NCT05777824 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: postoperative radiaotherapy
Description: postoperative radiotherapy (60Gy or 50Gy)
Study NCT06290778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Unified Protocol
Description: The Brief Transdiagnostic Treatment of Emotional Disorders Unified Protocol.
Study NCT06290778 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation regarding mental health challenges in fire service.
Study NCT06588101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compensation
Description: Potential participants are provided an e-gift card to Amazon or Second Cup as a reward for completing the enrollment questionnaire.
Study NCT06051357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 tablets
Description: HRS-5965 tablets for 12 weeks
Study NCT06134960 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KD-496
Description: Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells
Study NCT05395338 — intervention group
Intervention type: DRUG
Intervention: rt-PA
Description: Recombinant Tissue Plasminogen Activator
Study NCT04862377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poractant Alfa Intratracheal Suspension [Curosurf]
Description: Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg.
Study NCT06305390 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MRI
Description: 18F-PSMA PET/MRI
Study NCT06518655 — intervention group
Intervention type: OTHER
Intervention: Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
Description: Detection of volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
Study NCT04857281 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nVNS (gammaCore)
Description: The treatment will be self-administered using nVNS and will be applied for 4 weeks; a member of the study will provide the proper training on the correct use of nVNS. The patient will be instructed to use the nVNS in place of the rescue medications. When the nauseas gets bad enough that they feel to use a rescue medication they will first use the device on one side of the neck for two 2-minute stimulations and wait fifteen minutes to check if the stimulation works. If this does not help either, they will stimulate with an additional 2 stimulations and wait for another fifteen minutes. If there is no improvement rescue medication will be used. nVNS can be used up to, but no more than, 8 times a day.
Study NCT04089111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minute volume target of 100%
Description: Patients will be ventilated to reach minute volume target of %100 (100 ml per ideal body weight).
Study NCT04089111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minute volume target of 100%
Description: Patients will be ventilated to reach minute volume target of %100 (100 ml per ideal body weight).
Study NCT04089111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minute volume target to reach PaCO2 less than 45% (high tidal volume)
Description: Patients will be ventilated to reach minute volume target associated with PaCO2 less than 45%.
Study NCT04089111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minute volume target to reach PaCO2 less than 45% (high tidal volume)
Description: Patients will be ventilated to reach minute volume target associated with PaCO2 less than 45%.
Study NCT05152823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Therapy
Description: AAV9 carrying the IGHMBP2 gene.
Study NCT06461494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: baseline treatment
Description: hot pack will be applied for 10 minutes
Study NCT06461494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: baseline treatment
Description: hot pack will be applied for 10 minutes
Study NCT06256016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck pain massage
Description: Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, effleurages technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain.
Study NCT06256016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck and thoracic massage
Description: Subjects in this group will be treated with a neck muscle massage protocol. First, pressure inhibition techniques will be applied to the affected muscles. Then deep stroke technique will be performed on each muscle.~In addition, deep stroke technique will be applied along the thoracic paravertebral muscle.~Subjects will also perform an exercise protocol for neck pain.
Study NCT04874194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine Mepesuccinate
Description: Given SC
Study NCT04874194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT05284617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU6
Description: HU6 is being evaluated for its efficacy in improving cardiovascular function in obese subjects with HF with preserved ejection fraction (HFpEF).
Study NCT05284617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06535100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art therapy
Description: artistic therapy, wood painting, lithography, jewelry design, mud free shaping, expression workshop and training workshops
Study NCT04031677 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: Large en-bloc curative-intent surgery
Study NCT04862377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Poractant Alfa Intratracheal Suspension [Curosurf]
Description: Poractant alfa (Curosurf®):~First dose of treatment: 200mg/Kg. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg.
Study NCT04862377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 0.5 MG/ML
Description: Poractant alfa (Curosurf®) + Budesonide nebulizer solution (Budesonida Aldo-Unión 0.5mg/mL suspensión para inhalación por nebulizador®):~First dose: 200mg/Kg of surfactant + 0.25mg/Kg of budesonide. Further doses (up to a total maximum of 3 within first 48 hours of life): 100mg/Kg of surfactant + 0.25mg/Kg of budesonide.
Study NCT04031677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Description: * High grade LPS: ADM 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m2 Q3 weeks~* LMS: ADM 75 mg/m2 + DTIC 1g/m2 Q3 weeks~Note: the recommended dose of Doxorubicin (or Epirubicin) can be modified according to national/institutional guidelines, given that the minimal threshold must be Doxorubicin 60 mg/m2 per cycle (or the equivalent Epirubicin 95 mg/m2 per cycle); the recommended dose of Ifosfamide can be modified according to national/institutional guidelines, given that the minimal threshold must be 7.5 g/m2 per cycle; the recommended dose of Dacarbazine can be modified according to national/institutional guidelines, given that the minimal threshold must be 900 mg/m2 per cycle. The schedule of administration of above chemotherapies can be modified according to national/institutional guidelines provided that the minimal threshold of doses, and the treatment periods with chemotherapies remain the same.
Study NCT05918029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Citrate Extended Release Oral Tablet
Description: Oral potassium citrate extended-release tablet
Study NCT05918029 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule identical to active ingredient
Study NCT05918029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium Citrate and Citric Acid Oral Solution
Description: Oral potassium citrate and citric acid
Study NCT06633991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: verbal instructions
Description: verbal instructions inducing hope and optimism were administered as experimental condition vs neutral instructions (i.e., instructions not able to induce hope and optimism although realistic ones)
Study NCT06633991 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: verbal instructions
Description: verbal instructions inducing hope and optimism were administered as experimental condition vs neutral instructions (i.e., instructions not able to induce hope and optimism although realistic ones)
Study NCT04876144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kogito
Description: Users of the Kogito app progress throught the deep self-help intervention in a sequence of 5 modules. The base of the Kogito app is in the cognitive-behavioral therapy (CBT), relaxation techniques and peer support.~Module~1. Introduction to the CBT (psychoeducation) and deep breathing relaxation plus perinatal peer support videos. Emotional tracking.~2. Behavioral activization, relaxation techniques, CBT diary, psychoeducation on anxiety and depression, peer support.~3. CBT - vicious circle, progressive muscle relaxation, peer support content~4. Cognitive distortions, relaxation in imagination, peer support content~5. Cognitive restructuring, mindfulness relaxation, peer support content.~Progress in the Kogito app is conditional on the completion of various CBT tasks
Study NCT06557018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: liposomal bupivacaine group
Study NCT06557018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: traditional peri-articular injection
Description: traditional peri-articular injection group
Study NCT05366517 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dornier Aries 2 device
Description: For 6 weeks, patients will receive 6 sessions with active LiST probe, 2 session per week. The ARIES 2 device by Dornier will be used with a treatment protocol: 5000 SW, energy flux density = 0.096 mJ/mm2 (energy level 7) frequency = 5Hz
Study NCT05670704 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-119
Description: Patients receiving ARGX-119 IV or SC
Study NCT05670704 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving Placebo IV or SC
Study NCT06205966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BioGaia Pharax (L. reuteri PTA 5289 and DSM 17938)
Description: BioGaia Pharax drops (with PTA5289 and DSM 17938) with vitamin D3 will be manufactured and delivered by BioGaia AB as oil suspension.
Study NCT06205966 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product contains vitamin D3 and is identical to the active product but lacks L. reuteri.
Study NCT05224414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification for interpretation bias
Description: Sessions of scenario-based CBM-I training for OCD will be administered, based on the widely-used paradigm of ambiguous scenario training developed by Mathews and Mackintosh (2000), in which participants are presented with scenarios that are ambiguous in whether or not they are threatening. Participants will complete a computer task consisting of a series of written scenarios designed to improve interpretation and attributional biases; these scenarios conclude with word fragments, which participants must fill in to resolve the ambiguity.
Study NCT05224414 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychoeducation
Description: Sessions of psychoeducation will be administered, which will describe symptoms of anxiety, the nature of biased thinking in anxiety, and summarize common psychosocial as well as pharmacological treatments for anxiety. The sessions will provide relevant information but will not provide training in changing thinking styles.
Study NCT06486974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaF
Description: Group 1 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
Study NCT06486974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Na MFP
Description: Group 2 will be instructed to brush their teeth twice daily/2 minutes each time for the duration of this study
Study NCT05342792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Tislelizumab：200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
Study NCT05342792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
Study NCT05342792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine : 650 mg/m2 bid, orally, d1-21, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy
Study NCT04974476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT Exercise Training
Description: The HIIT total session duration will be approximately 30 minutes and will be composed of 10 sets of 60 seconds of high-intensity exercises, >80% of maximum heart rate (MHR), interspersed with a recovery period of 60 seconds of low-intensity exercise at 60% of MHR.
Study NCT06307795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANS014004
Description: Varying doses of ANS014004
Study NCT06192576 — intervention group
Intervention type: DRUG
Intervention: Olipudase alfa
Description: This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice.
Study NCT06611358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology Taping and Exercise
Description: Individuals meeting the inclusion criteria will receive kinesio taping applied to the temporomandibular joint by a physiotherapist every three days for two weeks. The kinesio tape will be applied along the origin-insertion line with zero tension. In addition to the kinesio taping, participants will follow a exercise program prescribed three days a week. This program will include isometric neck exercises (cervical flexion, extension, right and left lateral flexion, right and left rotation, and chin tuck exercises) and temporomandibular joint range of motion exercises (protrusion, retrusion, right and left lateral movement, and mouth opening-closing exercises). Each movement will be performed as 3 sets of 15 repetitions as part of the treatment protocol
Study NCT06611358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Convansionel Exercise
Description: This program will include isometric neck exercises (cervical flexion, extension, right and left lateral flexion, right and left rotation, and chin tuck exercises) and temporomandibular joint range of motion exercises (protrusion, retrusion, right and left lateral movement, and mouth opening-closing exercises). Each movement will be performed as 3 sets of 15 repetitions as part of the treatment protocol.
Study NCT06614972 — intervention group
Intervention type: DEVICE
Intervention: Balloon-expandable drug-eluting stent
Description: Balloon-expandable drug-eluting stent (BDES) is the device comprises of a balloon expandable sirolimus eluting stent and a delivery catheter that features a rapid exchange catheter design with a semi-compliant balloon located at its distal end.
Study NCT06485596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XVIVO Heart Assist Transport System
Description: Direct procurement of donor hearts from DCD donation
Study NCT06426433 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Proprioceptive Exercises
Description: In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Proprioceptive exercises aim to restore muscle balances, unconscious joint control with reactive muscle activations and feedforward joint control.
Study NCT06426433 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Upper Extremity Exercises
Description: In our study, participants were divided into two different exercise groups, starting with the same warm-up exercise program, and a 6-week exercise training program was implemented. To reduce the potential error resulting from daily life activities, exercise training was given to the non-dominant side of the participants. Upper extremity exercises are traditional rehabilitation exercises for strength, endurance and range of motion.
Study NCT05772208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: camrelizumab 200mg q3w
Study NCT05772208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: nimotuzumab 200mg qw
Study NCT06613776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 4 capsules of amoxicillin 500mg, 2 grams in total, one hour before surgery
Study NCT06613776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 empty capsules of amoxicillin 500mg (placebo), one hour before surgery
Study NCT05846165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Field-Cycling Imaging (FCI)
Description: FCI scan
Study NCT05799222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Bariatrix Meal Replacement Products
Description: Meal replacement products offered through the Massachusetts General Hospital Weight Center.
Study NCT06442995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space
Description: When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to the injection of morphine 2 mg into the epidural catheter + magnesium sulfate 500 mg
Study NCT06442995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injection of Isotonic saline + 2 mg morphine into the epidural space
Description: When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to Injection of morphine 2 mg into the epidural catheter + isotonic saline. This is the protocol the investigators use in daily practice for parturients who have undergone Caesarean section, in line with the French recommendations of anesthesia societies
Study NCT05772208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant chemotherapy and CCRT
Description: the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.
Study NCT05772208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy and CCRT
Description: the second and third neoajuvant chemotherapy with GP regimen (gemcitabine 1g/m2 d1，8 plus cisplatin 75mg/m2 ) concurrent chemotherapy: single cisplatin (80mg/m2) for two cycle definitive radiotherapy for primay lesion and lymph node region.